Status:
NO_LONGER_AVAILABLE
Compassionate Use of Stanate (TM) [Stannsoporfin]
Lead Sponsor:
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Conditions:
Neonatal Jaundice
Hyperbilirubinemia
Eligibility:
All Genders
12-1 years
Brief Summary
The purpose of this protocol is to make Stanate (TM) \[stannsoporfin, tin-mesoporphyrin\] available to infants who meet the following criteria: 1. the infant has a very high level of bilirubin withou...
Eligibility Criteria
Inclusion
- Term or near term neonate
- Elevated serum bilirubin
- Failing phototherapy
- Requires exchange transfusion
- Family refuses exchange transfusion on religious grounds
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00076960
Last Update
October 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073